Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Invested Capital (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Invested Capital for 8 consecutive years, with $480.9 million as the latest value for Q1 2026.

  • Quarterly Invested Capital changed 0.0% to $480.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $480.9 million through Feb 2026, changed 0.0% year-over-year, with the annual reading at $538.7 million for FY2025, 2.23% up from the prior year.
  • Invested Capital for Q1 2026 was $480.9 million at Nurix Therapeutics, down from $538.7 million in the prior quarter.
  • The five-year high for Invested Capital was $538.7 million in Q4 2025, with the low at $168.7 million in Q1 2024.
  • Average Invested Capital over 5 years is $350.1 million, with a median of $342.5 million recorded in 2022.
  • The sharpest move saw Invested Capital tumbled 38.42% in 2024, then skyrocketed 184.99% in 2025.
  • Over 5 years, Invested Capital stood at $303.7 million in 2022, then plummeted by 33.98% to $200.5 million in 2023, then soared by 162.85% to $527.0 million in 2024, then grew by 2.23% to $538.7 million in 2025, then fell by 10.74% to $480.9 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $480.9 million, $538.7 million, and $372.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.